Emerging targets and treatments in amyotrophic lateral sclerosis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21511200.
- Also identified by DOI 10.1016/S1474-4422(11)70024-2.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease that is currently untreatable. Many compounds have been tested in laboratory-based models and in patients with ALS, but so far only one drug, riluzole, has shown efficacy, yet it only slightly slows disease progression. Several new insights into the causes of motor neuron death have led to the identification of some important novel targets for intervention. At no time have studies involved such a wide range of innovations and such advanced technologies. Many promising studies are underway to test potential targets that will hopefully translate into meaningful therapeutics for patients with ALS.
Medical subject headings
- Amyotrophic Lateral Sclerosis
- Drug Delivery Systems
- Genetic Therapy